PMID- 19694823
OWN - NLM
STAT- MEDLINE
DCOM- 20091113
LR  - 20161125
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 55
IP  - 2
DP  - 2009 Aug
TI  - Urothelial carcinoma following augmentation cystoplasty: an aggressive variant 
      with distinct clinicopathological characteristics and molecular genetic 
      alterations.
PG  - 161-73
LID - 10.1111/j.1365-2559.2009.03363.x [doi]
AB  - AIMS: Patients who have undergone intestinal augmentation cystoplasty are at risk 
      for developing latent vesicle malignancy. The aim was to evaluate the 
      histological and immunohistochemical characteristics and molecular genetic 
      alterations in these neoplasms. METHODS AND RESULTS: Four patients developing 
      urothelial neoplasms after augmentation cystoplasty were included in the current 
      study. The mean age of the patients, including two men and two women, was 37 
      years. The latency from bladder augmentation to developing malignancy ranged from 
      17 to 21 years (mean 19 years). All patients died of cancer shortly after 
      diagnosis (mean 5 months). In the morphological evaluation, all tumours were 
      high-grade (grade 3) invasive urothelial carcinoma comprising various 
      architectural patterns with brisk mitoses and tumour necrosis. Three harboured 
      glandular differentiation and the remaining one showed squamous differentiation. 
      All cases revealed abnormal decreasing beta-catenin expression. Two tumours 
      showed nuclear expression of CDX2. On UroVysion fluorescence in situ 
      hybridization (FISH) analysis, all tumours displayed characteristic chromosomal 
      abnormalities. Point mutations of both FGFR3 and p53 genes were identified in one 
      case. CONCLUSIONS: Urothelial carcinomas developed after augmentation cystoplasty 
      are extremely aggressive and exhibit distinct morphological, immunohistochemical 
      and genetic characteristics. UroVysion FISH analysis may offer a surveillance 
      strategy in patients who undergo augmentation cystoplasty.
FAU - Sung, Ming-Tse
AU  - Sung MT
AD  - Department of Pathology, Chang Gung Memorial Hospital-Kaohsiung Medical Centre, 
      Chang Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Zhang, Shaobo
AU  - Zhang S
FAU - Lopez-Beltran, Antonio
AU  - Lopez-Beltran A
FAU - Montironi, Rodolfo
AU  - Montironi R
FAU - Wang, Mingsheng
AU  - Wang M
FAU - Davidson, Darrell D
AU  - Davidson DD
FAU - Koch, Michael O
AU  - Koch MO
FAU - Cain, Mark P
AU  - Cain MP
FAU - Rink, Richard C
AU  - Rink RC
FAU - Cheng, Liang
AU  - Cheng L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (CDX2 Transcription Factor)
RN  - 0 (CDX2 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (beta Catenin)
RN  - EC 2.7.10.1 (FGFR3 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
SB  - IM
MH  - Adult
MH  - CDX2 Transcription Factor
MH  - *Carcinoma, Transitional Cell/genetics/pathology
MH  - Cell Nucleus/metabolism
MH  - Chromosome Aberrations
MH  - Cystoscopy/*adverse effects
MH  - Exons
MH  - Fatal Outcome
MH  - Female
MH  - *Genes, p53
MH  - Homeodomain Proteins/genetics/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Mitosis/genetics
MH  - Necrosis/pathology
MH  - Nucleic Acid Amplification Techniques
MH  - Point Mutation
MH  - Polymerase Chain Reaction
MH  - Receptor, Fibroblast Growth Factor, Type 3/*genetics
MH  - Retrospective Studies
MH  - *Urinary Bladder Neoplasms/genetics/pathology
MH  - beta Catenin/genetics
EDAT- 2009/08/22 09:00
MHDA- 2009/11/17 06:00
CRDT- 2009/08/22 09:00
PHST- 2009/08/22 09:00 [entrez]
PHST- 2009/08/22 09:00 [pubmed]
PHST- 2009/11/17 06:00 [medline]
AID - HIS3363 [pii]
AID - 10.1111/j.1365-2559.2009.03363.x [doi]
PST - ppublish
SO  - Histopathology. 2009 Aug;55(2):161-73. doi: 10.1111/j.1365-2559.2009.03363.x.